Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.60
AZN's Cash to Debt is ranked higher than
60% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. AZN: 0.60 )
AZN' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: 0.6

Equity to Asset 0.36
AZN's Equity to Asset is ranked higher than
53% of the 820 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. AZN: 0.36 )
AZN' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.59
Current: 0.36

0.3
0.59
Interest Coverage 7.50
AZN's Interest Coverage is ranked higher than
56% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.95 vs. AZN: 7.50 )
AZN' s 10-Year Interest Coverage Range
Min: 6.94   Max: 100.5
Current: 7.5

6.94
100.5
F-Score: 4
Z-Score: 2.49
M-Score: -3.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 7.11
AZN's Operating margin (%) is ranked higher than
71% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.59 vs. AZN: 7.11 )
AZN' s 10-Year Operating margin (%) Range
Min: 12.32   Max: 38.09
Current: 7.11

12.32
38.09
Net-margin (%) 3.83
AZN's Net-margin (%) is ranked higher than
68% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.31 vs. AZN: 3.83 )
AZN' s 10-Year Net-margin (%) Range
Min: 6.86   Max: 29.72
Current: 3.83

6.86
29.72
ROE (%) 4.53
AZN's ROE (%) is ranked higher than
69% of the 874 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. AZN: 4.53 )
AZN' s 10-Year ROE (%) Range
Min: 10.72   Max: 45.6
Current: 4.53

10.72
45.6
ROA (%) 1.76
AZN's ROA (%) is ranked higher than
67% of the 910 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.02 vs. AZN: 1.76 )
AZN' s 10-Year ROA (%) Range
Min: 4.6   Max: 21.04
Current: 1.76

4.6
21.04
ROC (Joel Greenblatt) (%) 31.12
AZN's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.17 vs. AZN: 31.12 )
AZN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 33.33   Max: 192.75
Current: 31.12

33.33
192.75
Revenue Growth (%) -5.10
AZN's Revenue Growth (%) is ranked higher than
57% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. AZN: -5.10 )
AZN' s 10-Year Revenue Growth (%) Range
Min: -43.4   Max: 87.7
Current: -5.1

-43.4
87.7
EBITDA Growth (%) -14.50
AZN's EBITDA Growth (%) is ranked higher than
57% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. AZN: -14.50 )
AZN' s 10-Year EBITDA Growth (%) Range
Min: -39.5   Max: 112.8
Current: -14.5

-39.5
112.8
EPS Growth (%) -29.50
AZN's EPS Growth (%) is ranked higher than
57% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. AZN: -29.50 )
AZN' s 10-Year EPS Growth (%) Range
Min: -29.5   Max: 71.5
Current: -29.5

-29.5
71.5
» AZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

AZN Guru Trades in Q4 2013

Stanley Druckenmiller 360,500 sh (New)
Francis Chou 13,000 sh (New)
Pioneer Investments 651,839 sh (+10.46%)
Charles Brandes 2,503,848 sh (+5.16%)
Steven Cohen 533,262 sh (+0.22%)
Murray Stahl 12,020 sh (unchged)
NWQ Managers 85,450 sh (-0.47%)
Manning & Napier Advisors, Inc 490,878 sh (-3.55%)
Jim Simons 2,715,400 sh (-6.81%)
HOTCHKIS & WILEY 3,689,214 sh (-24.9%)
David Dreman 106,975 sh (-40.32%)
John Hussman 28,000 sh (-58.82%)
» More
Q1 2014

AZN Guru Trades in Q1 2014

Joel Greenblatt 95,518 sh (New)
John Hussman 228,000 sh (+714.29%)
David Dreman 135,439 sh (+26.61%)
Murray Stahl 13,106 sh (+9.03%)
NWQ Managers 85,450 sh (unchged)
Stanley Druckenmiller 360,500 sh (unchged)
Francis Chou 13,000 sh (unchged)
HOTCHKIS & WILEY Sold Out
Manning & Napier Advisors, Inc 459,569 sh (-6.38%)
Pioneer Investments 459,298 sh (-29.54%)
Steven Cohen 367,034 sh (-31.17%)
Charles Brandes 1,333,894 sh (-46.73%)
Jim Simons 1,429,000 sh (-47.37%)
» More
Q2 2014

AZN Guru Trades in Q2 2014

Jeremy Grantham 28,000 sh (New)
Paul Tudor Jones 27,100 sh (New)
Mario Gabelli 40,400 sh (New)
Louis Moore Bacon 40,000 sh (New)
George Soros 150,000 sh (New)
Jim Simons 1,794,800 sh (+25.6%)
Francis Chou 13,000 sh (unchged)
Steven Cohen 370,800 sh (unchged)
Daniel Loeb 1,000,000 sh (unchged)
Steven Cohen 225,000 sh (unchged)
Joel Greenblatt Sold Out
Murray Stahl 13,000 sh (-0.81%)
John Hussman 223,500 sh (-1.97%)
David Dreman 117,832 sh (-13%)
NWQ Managers 64,475 sh (-24.55%)
Manning & Napier Advisors, Inc 309,030 sh (-32.76%)
Stanley Druckenmiller 208,900 sh (-42.05%)
Pioneer Investments 225,804 sh (-50.84%)
Charles Brandes 386,058 sh (-71.06%)
» More
Q3 2014

AZN Guru Trades in Q3 2014

Steven Cohen 611,100 sh (+64.81%)
Mario Gabelli 41,900 sh (+3.71%)
Jim Simons 1,847,100 sh (+2.91%)
Manning & Napier Advisors, Inc 317,180 sh (+2.64%)
Pioneer Investments 227,221 sh (+0.63%)
Steven Cohen 400,000 sh (unchged)
George Soros 150,000 sh (unchged)
Murray Stahl 13,000 sh (unchged)
Francis Chou 13,000 sh (unchged)
NWQ Managers 64,475 sh (unchged)
Jeremy Grantham Sold Out
Charles Brandes Sold Out
Paul Tudor Jones Sold Out
Stanley Druckenmiller Sold Out
David Dreman 117,003 sh (-0.7%)
John Hussman 173,500 sh (-22.37%)
Louis Moore Bacon 30,000 sh (-25%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2014-09-30 Sold Out 0.35%$68.49 - $76.31 $ 73.911%0
John Hussman 2014-09-30 Reduce -22.37%0.29%$68.49 - $76.31 $ 73.911%173500
Charles Brandes 2014-06-30 Reduce -71.06%0.78%$62.45 - $81.09 $ 73.912%386058
Joel Greenblatt 2014-06-30 Sold Out 0.09%$62.45 - $81.09 $ 73.912%0
George Soros 2014-06-30 New Buy0.08%$62.45 - $81.09 $ 73.912%150000
Mario Gabelli 2014-06-30 New Buy0.02%$62.45 - $81.09 $ 73.912%40400
NWQ Managers 2014-06-30 Reduce -24.55%0.01%$62.45 - $81.09 $ 73.912%64475
John Hussman 2014-03-31 Add 714.29%0.96%$58.51 - $68.15 $ 73.9115%228000
HOTCHKIS & WILEY 2014-03-31 Sold Out 0.93%$58.51 - $68.38 $ 73.9115%0
Charles Brandes 2014-03-31 Reduce -46.73%0.84%$58.51 - $68.15 $ 73.9115%1333894
David Dreman 2014-03-31 Add 26.61%0.14%$58.51 - $68.38 $ 73.9115%135439
Joel Greenblatt 2014-03-31 New Buy0.09%$58.51 - $68.38 $ 73.9115%95518
David Dreman 2013-12-31 Reduce -40.32%0.34%$49.72 - $59.5 $ 73.9136%106975
HOTCHKIS & WILEY 2013-12-31 Reduce -24.9%0.3%$49.72 - $59.5 $ 73.9136%3689214
John Hussman 2013-12-31 Reduce -58.82%0.11%$49.72 - $59.5 $ 73.9136%28000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 97.60
AZN's P/E(ttm) is ranked higher than
68% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.00 vs. AZN: 97.60 )
AZN' s 10-Year P/E(ttm) Range
Min: 6.07   Max: 99.04
Current: 97.6

6.07
99.04
P/B 4.60
AZN's P/B is ranked higher than
64% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. AZN: 4.60 )
AZN' s 10-Year P/B Range
Min: 2.31   Max: 7.02
Current: 4.6

2.31
7.02
P/S 3.70
AZN's P/S is ranked higher than
73% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.96 vs. AZN: 3.70 )
AZN' s 10-Year P/S Range
Min: 1.6   Max: 4.13
Current: 3.7

1.6
4.13
PFCF 20.90
AZN's PFCF is ranked higher than
93% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. AZN: 20.90 )
AZN' s 10-Year PFCF Range
Min: 6.22   Max: 38.17
Current: 20.9

6.22
38.17
EV-to-EBIT 55.01
AZN's EV-to-EBIT is ranked higher than
71% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.72 vs. AZN: 55.01 )
AZN' s 10-Year EV-to-EBIT Range
Min: 4.5   Max: 55.4
Current: 55.01

4.5
55.4
Shiller P/E 15.30
AZN's Shiller P/E is ranked higher than
96% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.40 vs. AZN: 15.30 )
AZN' s 10-Year Shiller P/E Range
Min: 8.07   Max: 31.15
Current: 15.3

8.07
31.15
Current Ratio 0.95
AZN's Current Ratio is ranked lower than
52% of the 891 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. AZN: 0.95 )
AZN' s 10-Year Current Ratio Range
Min: 0.64   Max: 2.03
Current: 0.95

0.64
2.03
Quick Ratio 0.83
AZN's Quick Ratio is ranked higher than
51% of the 890 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. AZN: 0.83 )
AZN' s 10-Year Quick Ratio Range
Min: 0.54   Max: 2.03
Current: 0.83

0.54
2.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.80
AZN's Dividend Yield is ranked higher than
93% of the 518 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. AZN: 3.80 )
AZN' s 10-Year Dividend Yield Range
Min: 1.59   Max: 6.83
Current: 3.8

1.59
6.83
Dividend Payout 3.43
AZN's Dividend Payout is ranked higher than
81% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. AZN: 3.43 )
AZN' s 10-Year Dividend Payout Range
Min: 0.24   Max: 4.87
Current: 3.43

0.24
4.87
Dividend growth (3y) 3.20
AZN's Dividend growth (3y) is ranked higher than
78% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. AZN: 3.20 )
AZN' s 10-Year Dividend growth (3y) Range
Min: -6.3   Max: 30.1
Current: 3.2

-6.3
30.1
Yield on cost (5-Year) 5.38
AZN's Yield on cost (5-Year) is ranked higher than
93% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.46 vs. AZN: 5.38 )
AZN' s 10-Year Yield on cost (5-Year) Range
Min: 2.25   Max: 9.67
Current: 5.38

2.25
9.67
Share Buyback Rate 4.60
AZN's Share Buyback Rate is ranked higher than
92% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. AZN: 4.60 )
AZN' s 10-Year Share Buyback Rate Range
Min: 43.7   Max: -123.9
Current: 4.6

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.20
AZN's Price/DCF (Projected) is ranked higher than
93% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.00 vs. AZN: 1.20 )
AZN' s 10-Year Price/DCF (Projected) Range
Min: 0.49   Max: 4.43
Current: 1.2

0.49
4.43
Price/Median PS Value 1.50
AZN's Price/Median PS Value is ranked higher than
65% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.33 vs. AZN: 1.50 )
AZN' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 2.47
Current: 1.5

0.69
2.47
Earnings Yield (Greenblatt) 1.80
AZN's Earnings Yield (Greenblatt) is ranked higher than
70% of the 893 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. AZN: 1.80 )
AZN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.8   Max: 22.2
Current: 1.8

1.8
22.2
Forward Rate of Return (Yacktman) -7.67
AZN's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.33 vs. AZN: -7.67 )
AZN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.1   Max: 34.9
Current: -7.67

-9.1
34.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:AZN.Sweden, AZNDF.USA, AZN.UK, ZEGA.Germany, ZEG.Germany, AZNCF.USA, AZN N.Mexico
AstraZeneca PLC was incorporated in England and Wales on 17 June 1992. From February 1993 until April 1999, the Company was called Zeneca Group PLC. On 6 April 1999, the Company changed its name to AstraZeneca PLC. It is a biopharmaceutical company. The Company focuses on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). The Company is also engaged in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. It operates in more than 100 countries.
» More Articles for AZN

Headlines

Articles On GuruFocus.com
Blackhill Bets Almost Half of Portfolio on Williams-Sonoma Nov 10 2014 
A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Nov 09 2014 
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
Can Pfizer Make Up Its Loss? May 09 2014 
Abbott Capturing Incremental Market Share Mar 18 2014 
Abbvie's Humira Continues to be a Powerful Catalyst for Growth Mar 18 2014 
10 British Stocks to Consider Feb 20 2014 


More From Other Websites
AstraZeneca/Amgen's Brodalumab Excels in Psoriasis Study Nov 26 2014
Intra-Cellular Commences Phase III Schizophrenia Study Nov 26 2014
AstraZeneca's (AZN) Respiratory Drug Approved in the EU Nov 26 2014
As Deadline Passes, Will AstraZeneca plc Attract A New Bid From Pfizer Inc? Nov 26 2014
Pfizer to join forces with AstraZeneca? Nov 26 2014
Astrazeneca and Amgen hail success in psoriasis treatment trial Nov 26 2014
Pfizer to renew pursuit of AstraZeneca? Nov 26 2014
Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of... Nov 25 2014
Is It Too Late To Buy November’s Winners, AstraZeneca plc And Vodafone Group plc? Nov 25 2014
Aviva investors should not sleepwalk into deal Nov 25 2014
Novartis' Psoriasis Drug Cosentyx Backed for EU Approval Nov 24 2014
FTSE rally pulls back from two-month high as Petrofac slump weighs Nov 24 2014
Buying Glaxo's Biotech Stock Throwbacks Proves Profitable Nov 24 2014
FTSE rally pauses near two-month high as Petrofac slump weighs Nov 24 2014
6:57 am AstraZeneca announced that Duaklir Genuair has been granted Marketing Authorization by the... Nov 24 2014
Astrazeneca COPD treatment granted marketing authorisation in Europe Nov 24 2014
Duaklir® Genuair® approved in the European Union for chronic obstructive pulmonary disease Nov 24 2014
Forget about a Fed rate hike in 2015: Pro Nov 23 2014
UK drugmakers back in spotlight as bidders free to return Nov 22 2014
AstraZeneca Announces Plans to Expand its Frederick, Maryland Biologics Manufacturing Center Nov 21 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK